Moshe E Gatt researcher
גת, משה, 1967-
Gatt, Moshe, 1967-
VIAF ID: 2680161453832164330003 (Personal)
Permalink: http://viaf.org/viaf/2680161453832164330003
Preferred Forms
-
- 100 0 _ ‡a Moshe E Gatt ‡c researcher
-
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study | |
A Bortezomib-Based Protocol Induces a High Rate of Complete Remission with Minor Toxicity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia | |
Daratumumab for relapsed AL amyloidosis - when cumulative real-world data precedes clinical trials: A multisite study and systematic literature review | |
Daratumumab resistance is frequent in advanced stage multiple myeloma patients irrespectively of CD38 expression, and is related to dismal prognosis. | |
Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature. | |
The impact of anti-bacterial prophylaxis on the outcome of patients treated with venetoclax-based regimens for relapsed/refractory plasma cell dyscrasias: Real-life data | |
Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group | |
Romidepsin-Bendamustine Combination for Relapsed/Refractory T Cell Lymphoma | |
Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study | |
The use of serum free light chain dimerization patterns assist in the diagnosis of AL amyloidosis. |